# Azcuris

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/azcuris

- Industry: Pharmaceuticals
- Headquarters: Sejong, South Korea
- Website: www.azcuris.com/
- Total disclosed funding: $3.4M
- Latest round: Series B (Apr 30, 2026)
- Investors on record: 4

## About

Azcuris is a South Korea-based company focused on developing innovative small-molecule therapeutics that modulate cytokine signaling pathways to prevent and treat immune diseases.Founded in 2018 and headquartered in Sejong, South Korea, Azcuris specializes in drug discovery for immune-related conditions. In April 2026, Azcuris raised KRW 5 billion in series B funding from BNH Investment, Atinum Investment, KB Investment, and Partners Investment. Azcuris specializes in the development of innovative small-molecule therapeutics aimed at modulating cytokine signaling pathways to prevent and treat immune diseases. Their primary offering revolves around a proprietary drug discovery platform that focuses on small-molecule immune therapeutics. This platform is designed to control the early stages of immune responses, effectively blocking disease progression. Azcuris targets various immune-related conditions and aims to provide solutions for patients suffering from chronic inflammatory diseases and autoimmune disorders. The company serves a diverse client base, including research institutions, pharmaceutical companies, and healthcare providers, primarily within the Asian and European markets where immunotherapy is gaining traction.Azcuris generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research organizations, focusing on the commercialization of their drug discovery platform. Typically, transactions involve licensing agreements where clients pay for access to Azcuris's proprietary technologies or collaborative agreements that may include milestone payments based on research outcomes. The company may also engage in joint ventures with larger firms to facilitate the development and distribution of their therapeutic products. While specific pricing plans for their services are not disclosed, revenue is driven by these collaborations, which align with their mission to innovate in the field of immunotherapy. The flagship offerings, centered around cytokine modulation, position Azcuris to capitalize on the growing demand for specialized immune therapeutics in the market. The company plans to expand its reach into European markets by the end of 2023, capitalizing on the increasing demand for advanced immunotherapies. This funding is aimed at enhancing their proprietary drug discovery platform and facilitating entry into these new markets.

## Funding rounds

- Series B, Apr 30, 2026, $3.4M — KB Investment, Atinum Investment, Partners Investment, BNH Investment

## Investors

- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B
- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series B
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series B
- BNH Investment (https://capitalatlas.ai/funds/bnh-investment) — Series B